Optimal duration of anti-TB treatment in patients with diabetes: Nine or six months?

Chest

Volumn 147, Issue 2, 2015, Pages 520-528

  Wang, Jann Yuan ^a   Lee, Ming Chia ^b   Shu, Chin Chung ^a   Lee, Chih Hsin ^c   Lee, Li Na ^a   Chao, Kun Mao ^d   Chang, Feng Yee ^e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Buddist Tzu Chi College of Nursing   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE; AGED; ARTICLE; BACTERIUM CULTURE; CLINICAL SUPERVISION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SHORT COURSE THERAPY; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; DIRECTLY OBSERVED THERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENT DISEASE; TUBERCULOSIS, PULMONARY;

AGED; ANTITUBERCULAR AGENTS; DIABETES MELLITUS; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; TUBERCULOSIS, PULMONARY;

EID: 84928046667     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0918     Document Type: Article

References (27)

1. World Health Organization. G lobal Tuberculosis Control. Geneva, Switzerland: World Health Organization; 2011.
2. British Th oracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months aft er the end of chemotherapy. Am Rev Respir Dis. 1982; 126 ( 3): 460-462.
3. East and Central African/British Medical Research Council Fift h Collaborative Study. Controlled clinical trial of 4 shortcourse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: fi nal report. Tubercle. 1986; 67 ( 1): 5-15.
4. Weis SE, Slocum PC, Blais FX, et al. The eff ect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994; 330 ( 17): 1179-1184.
5. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva, Switzerland: World Health Organization; 2009.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27 ( 5): 1047-1053.
7. Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol. 2007; 37 ( 5): 518-524.
8. Stalenhoef JE, Alisjahbana B, Nelwan EJ, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis. 2008; 27 ( 2): 97-103.
9. Tsukaguchi K, Okamura H, Ikuno M, et al. The relation between diabetes mellitus and IFN-gamma, IL-12 and IL-10 productions by CD4 1 alpha beta Tcells and monocytes in patients with pulmonary tuberculosis [in Japanese]. Kekkaku. 1997; 72 ( 11): 617-622.
10. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fl uoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Th orax. 2006; 61 ( 10): 903-908.
11. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011; 9: 81.
12. The national health insurance statistics. Bureau of National Health Insurance website. http://www. nhi. gov. tw/English/ webdata/webdata. aspx?menu 5 11&menu- id 5 296&webdata-id 5 1942&WD-ID 5 296. Published 2011. Accessed September 24, 2014.
13. Lee CH, Lee MC, Lin HH, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS ONE. 2012; 7 ( 5): e37978.
14. Luh KT, ed. Taiwan Guidelines for TB Diagnosis and Treatment. 5th ed. Taipei, Taiwan: Centers for Disease Control, R. O. C. (Taiwan); 2013.
15. Chang CH SW, Jiang YD, et al. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med. 2010;27(6): 636-643.
16. Lee M-C, Lee C-H, Shu C-C, et al. The impact of diabetes mellitus and its control on the development of tuberculosis: a nationwide longitudinal study in Taiwan. Pharmacoepidemiol Drug Saf. 2013; 22 ( 9): 995-1003.
17. Public Assistance Act. 7th ed. Taipei, Taiwan (R. O. C): Ministry of the Interior; 2010.
18. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Th orax. 2013; 68 ( 3): 214-220.
19. Taiwan tuberculosis control report. Centers for Disease Control, Department of Health website. http://www. cdc. gov. tw/uploads/fi les/201206/ccfec372-80f3-4256-9c3a-077fb 8ccfa08. pdf. Published 2011. Accessed September 24, 2014.
20. Blumberg HM, Burman WJ, Chaisson RE, et al; American Th oracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Th oracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med. 2003; 167 ( 4): 603-662.
21. Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009; 137 ( 2): 203-210.
22. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Eff ects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Th er. 2001; 69 ( 6): 400-406.
23. Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Eff ect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Th er. 2004; 75 ( 3): 157-162.
24. Gwilt PR, Nahhas RR, Tracewell WG. The eff ects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991; 20 ( 6): 477-490.
25. Wang JY, Hsu HL, Yu MC, et al; TAMI Group. Mixed infection with Beijing and non-Beijing strains in pulmonary tuberculosis in Taiwan: prevalence, risk factors, and dominant strain. Clin Microbiol Infect. 2011; 17 ( 8): 1239-1245.
26. Aber VR, Nunn AJ. Short term chemotherapy of tuberculosis. Factors aff ecting relapse following short term chemotherapy [in French]. Bull Int Union Tuberc. 1978; 53 ( 4): 276-280.
27. Wang JY, Lee LN, Lai HC, et al. Prediction of the tuberculosis reinfection proportion from the local incidence. J Infect Dis. 2007; 196 ( 2): 281-288.